Paty B W, Harmon J S, Marsh C L, Robertson R P
Pacific Northwest Research Institute, Seattle, Washington 98122, USA.
Transplantation. 2002 Feb 15;73(3):353-7. doi: 10.1097/00007890-200202150-00007.
Until recently, islet allotransplantation for type 1 diabetic patients has been largely unsuccessful. Previous pharmacologic studies of single drugs have suggested that one factor contributing to this poor success is toxicity of immunosuppressive drugs on transplanted islets. However, no comprehensive study of agents currently used for islet transplantation has been previously reported. Consequently, we exposed HIT-T15 cells and Wistar rat islets to various concentrations of five immunosuppressive agents for 48 and 24 hr, respectively, and measured glucose-stimulated insulin secretion during subsequent static incubations. Results are expressed as percent reduction of insulin secretion at the lower and upper limits, respectively, of plasma drug concentrations used in clinical transplantation compared with control (no drug exposure). Insulin secretion from HIT-T15 cells was significantly inhibited by 74% and 90% after exposure to methylprednisolone (P<0.05), 11% and 24% after exposure to cyclosporine (P<0.01), 60% and 83% after exposure to mycophenolate (P<0.05), 56% and 63% after exposure to sirolimus (P<0.001), and 10% and 20% after exposure to tacrolimus (P<0.001). Insulin secretion from Wistar rat islets was reduced by 0% and 48% after exposure to mycophenolate (P<0.001) and 20% and 31% after exposure to tacrolimus (P<0.05). No reduction in insulin secretion was observed from either HIT-T15 cells or rat islets after exposure to daclizumab. The results support the hypothesis that toxicity of certain immunosuppressive drugs on beta-cell function plays a role in the poor success of islet allotransplantation. This is especially true of intrahepatically transplanted islets, which are exposed to higher portal concentrations of immunosuppressive agents. These findings support the use of low-dose immunosuppressive drug protocols in clinical islet transplantation.
直到最近,1型糖尿病患者的胰岛同种异体移植在很大程度上并不成功。以往对单一药物的药理学研究表明,导致这种不佳成功率的一个因素是免疫抑制药物对移植胰岛的毒性。然而,此前尚未有关于目前用于胰岛移植的药物的全面研究报告。因此,我们分别将HIT-T15细胞和Wistar大鼠胰岛暴露于五种免疫抑制药物的不同浓度下48小时和24小时,并在随后的静态孵育过程中测量葡萄糖刺激的胰岛素分泌。结果分别表示为与对照(未暴露于药物)相比,临床移植中使用的血浆药物浓度下限和上限时胰岛素分泌减少的百分比。暴露于甲泼尼龙后,HIT-T15细胞的胰岛素分泌分别显著抑制了74%和90%(P<0.05),暴露于环孢素后分别抑制了11%和24%(P<0.01),暴露于霉酚酸酯后分别抑制了60%和83%(P<0.05),暴露于西罗莫司后分别抑制了56%和63%(P<0.001),暴露于他克莫司后分别抑制了10%和20%(P<0.001)。暴露于霉酚酸酯后,Wistar大鼠胰岛的胰岛素分泌减少了0%和48%(P<0.001),暴露于他克莫司后减少了20%和31%(P<0.05)。暴露于达利珠单抗后,HIT-T15细胞或大鼠胰岛的胰岛素分泌均未观察到减少。这些结果支持了这样一种假设,即某些免疫抑制药物对β细胞功能的毒性在胰岛同种异体移植不佳的成功率中起作用。对于肝内移植的胰岛尤其如此,因为它们会接触到更高门静脉浓度的免疫抑制药物。这些发现支持在临床胰岛移植中使用低剂量免疫抑制药物方案。